HLS Therapeutics (HLS) Set to Announce Quarterly Earnings on Thursday

HLS Therapeutics (TSE:HLSGet Rating) will issue its quarterly earnings data before the market opens on Thursday, August 11th. Analysts expect the company to announce earnings of C($0.08) per share for the quarter.

HLS Therapeutics (TSE:HLSGet Rating) last released its earnings results on Thursday, May 5th. The company reported C($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.10) by C($0.04). The business had revenue of C$18.44 million for the quarter, compared to analyst estimates of C$19.39 million.

HLS Therapeutics Trading Down 0.5 %

HLS opened at C$12.77 on Thursday. The company has a debt-to-equity ratio of 59.50, a current ratio of 1.67 and a quick ratio of 1.26. The company’s 50 day simple moving average is C$12.85 and its two-hundred day simple moving average is C$13.94. HLS Therapeutics has a 1-year low of C$11.00 and a 1-year high of C$20.52. The firm has a market capitalization of C$414.62 million and a price-to-earnings ratio of -26.66.

Wall Street Analysts Forecast Growth

HLS has been the topic of several analyst reports. Clarus Securities reaffirmed a “buy” rating and set a C$26.50 price target on shares of HLS Therapeutics in a research report on Monday, July 25th. Bloom Burton reaffirmed a “buy” rating and set a C$22.00 price target on shares of HLS Therapeutics in a research report on Tuesday, July 26th.

HLS Therapeutics Company Profile

(Get Rating)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia.

Featured Stories

Earnings History for HLS Therapeutics (TSE:HLS)

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.